The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Marrow Access Technologies sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Marrow Access Technologies is a medical equipment company that develops natural biologic solutions for use in the knee, hip, ankle, spine, elbow, and shoulder. The company offers its flagship product SmartShot, a marrow access device that helps surgeons treat cartilage lesions of the ankle. SmartShot device provides greater access to stem cell-rich marrow with less bone disruption enabling patients with cartilage defects to recover soon. Marrow Access is headquartered in Minnetonka, Minnesota, the US.
The key metrics of Marrow Access Technologies related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Marrow Access Technologies is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Marrow Access Technologies.
For a detailed understanding of the performance of Marrow Access Technologies, buy the report here.